Continuus Pharmaceuticals Applies to Make Fentanyl for Research
Estimated reading time: 3–5 minutes
Continuus Pharmaceuticals has applied to become a registered bulk manufacturer of a controlled drug. The notice was published in the Federal Register on August 21, 2025.
The application is for the drug fentanyl. Fentanyl is listed as a Schedule II controlled substance. This means it is tightly regulated.
The company is located at 256 West Cummings Park, Woburn, Massachusetts 01801.
Continuus Pharmaceuticals plans to make fentanyl in bulk. The drug made is only for research and development. The company is not allowed to do anything else with this drug under this application.
The Drug Enforcement Administration, known as the DEA, is handling this application. The public can send comments or objections about the application. People can also ask for a hearing.
The deadline to comment or request a hearing is October 20, 2025. All comments must be sent online through the Federal eRulemaking Portal at https://www.regulations.gov. When you send a comment, you will get a tracking number. Comments may not show up for public view right away.
This notice was signed by Justin Wood, Acting Deputy Assistant Administrator of the DEA.
The notice was filed with the Federal Register on August 20, 2025.
No other activities with fentanyl are allowed under this registration. The only use is for research and development by Continuus Pharmaceuticals.
Legal Disclaimer
This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.
